MX2016006894A - Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. - Google Patents
Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.Info
- Publication number
- MX2016006894A MX2016006894A MX2016006894A MX2016006894A MX2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A MX 2016006894 A MX2016006894 A MX 2016006894A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- cdk
- jak
- treatment
- pim
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000025113 myeloid leukemia Diseases 0.000 abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940122016 Pim kinase inhibitor Drugs 0.000 abstract 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a una combinación farmacéutica que comprende (a) un compuesto inhibidor de JAK, (b) un inhibidor de CDK, y (c) un compuesto inhibidor de quinasa PIM, y opcionalmente, al menos un portador farmacéuticamente aceptable para uso simultáneo, separado o uso secuencial, en particular para el tratamiento de un neoplasma mieloide o leucemia; una composición farmacéutica que comprende tal combinación; el uso de tal combinación para la preparación de un medicamento para el tratamiento de la neoplasia mieloide o leucemia; un paquete o producto comercial que comprende tal combinación como una preparación combinada para uso simultáneo, separado o secuencial; y a un método de tratamiento de un mamífero, especialmente un ser humano.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909547P | 2013-11-27 | 2013-11-27 | |
| US201462081210P | 2014-11-18 | 2014-11-18 | |
| US201462082174P | 2014-11-20 | 2014-11-20 | |
| PCT/US2014/067352 WO2015081083A1 (en) | 2013-11-27 | 2014-11-25 | Combination therapy comprising an inhibitor of jak, cdk and pim |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006894A true MX2016006894A (es) | 2016-08-17 |
Family
ID=52302307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006894A MX2016006894A (es) | 2013-11-27 | 2014-11-25 | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160375024A1 (es) |
| EP (1) | EP3074043A1 (es) |
| JP (1) | JP2016538305A (es) |
| KR (1) | KR20160090814A (es) |
| CN (1) | CN105764528A (es) |
| AU (3) | AU2014354821A1 (es) |
| CA (1) | CA2929620A1 (es) |
| MX (1) | MX2016006894A (es) |
| RU (1) | RU2016125133A (es) |
| WO (1) | WO2015081083A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106336412A (zh) * | 2015-07-10 | 2017-01-18 | 南开大学 | 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物 |
| MX2020010556A (es) * | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
| KR20210098957A (ko) * | 2018-09-25 | 2021-08-11 | 임팩트 바이오메디신스, 인코포레이티드 | 골수증식성 장애를 치료하는 방법 |
| CA3117678A1 (en) | 2018-10-31 | 2020-05-07 | Stemline Therapeutics, Inc. | Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents |
| CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3838903B1 (en) | 2005-12-13 | 2023-11-22 | Incyte Holdings Corporation | Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor |
| PT2331547E (pt) * | 2008-08-22 | 2014-10-29 | Novartis Ag | Compostos de pirrolopirimidina como inibidores de cdk |
| KR101345920B1 (ko) * | 2008-09-02 | 2014-02-06 | 노파르티스 아게 | 키나제 억제제로서의 피콜린아미드 유도체 |
-
2014
- 2014-11-25 AU AU2014354821A patent/AU2014354821A1/en not_active Abandoned
- 2014-11-25 JP JP2016534733A patent/JP2016538305A/ja active Pending
- 2014-11-25 WO PCT/US2014/067352 patent/WO2015081083A1/en not_active Ceased
- 2014-11-25 EP EP14824963.4A patent/EP3074043A1/en not_active Withdrawn
- 2014-11-25 KR KR1020167013657A patent/KR20160090814A/ko not_active Withdrawn
- 2014-11-25 RU RU2016125133A patent/RU2016125133A/ru unknown
- 2014-11-25 CA CA2929620A patent/CA2929620A1/en not_active Abandoned
- 2014-11-25 US US15/039,869 patent/US20160375024A1/en not_active Abandoned
- 2014-11-25 MX MX2016006894A patent/MX2016006894A/es unknown
- 2014-11-25 CN CN201480064659.1A patent/CN105764528A/zh active Pending
-
2017
- 2017-09-20 US US15/710,069 patent/US20180071296A1/en not_active Abandoned
- 2017-10-11 AU AU2017245332A patent/AU2017245332A1/en not_active Abandoned
-
2018
- 2018-11-02 AU AU2018256668A patent/AU2018256668A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160090814A (ko) | 2016-08-01 |
| CN105764528A (zh) | 2016-07-13 |
| EP3074043A1 (en) | 2016-10-05 |
| US20180071296A1 (en) | 2018-03-15 |
| RU2016125133A (ru) | 2018-01-09 |
| JP2016538305A (ja) | 2016-12-08 |
| AU2018256668A1 (en) | 2018-11-22 |
| AU2014354821A1 (en) | 2016-05-26 |
| CA2929620A1 (en) | 2015-06-04 |
| WO2015081083A1 (en) | 2015-06-04 |
| US20160375024A1 (en) | 2016-12-29 |
| AU2017245332A1 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| PH12017500281A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| MY176235A (en) | Compounds that inhibit mcl-1 protein | |
| PH12016500933A1 (en) | Novel combination treatment for acute myeloid leukemia (aml) | |
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| MX366899B (es) | Nuevos compuestos. | |
| ZA201603342B (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM | |
| MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
| MX2016001683A (es) | Combinaciones de inhibidores de quinasa pim. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MY179509A (en) | Piperazine derivatives having multimodal activity against pain | |
| MX2015004362A (es) | Derivados de ketamina. | |
| MX2016006604A (es) | Derivados de piperidina con actividad multimodal contra el dolor. | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| MX376029B (es) | Compuestos de isoindol. | |
| MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
| MY193423A (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| MX2015011588A (es) | Tratamiento de combinacion. | |
| IN2013MU03118A (es) | ||
| MX362533B (es) | Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa. | |
| MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. |